文献速递心力衰竭与心肌病

心脏重编程及Gata4过表达减轻HFpEF纤维化并改善舒张功能

Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.
PubMed 文献 · Circulation · 2024-12-14

该研究在Tcf21iCre/Tomato/MGTH2A转基因小鼠中采用高脂饮食联合一氧化氮合酶抑制建立射血分数保留的心力衰竭(HFpEF)模型,通过心脏重编程(MGTH过表达)观察到舒张功能障碍、心肌肥厚、纤维化、炎症及毛细血管丢失改善。单细胞与空间转录组显示多个心脏成纤维细胞(CF)簇上调促纤维化基因,而4个重编程因子中仅Gata4过表达即可抑制CF活化、减少纤维化并改善舒张功能,且不产生新的诱导心肌细胞。

要点

  • MGTH过表达的心脏重编程可改善HFpEF小鼠的舒张功能障碍与纤维化。
  • 4个重编程因子中仅Gata4过表达即可减轻纤维化并改善舒张功能。
  • Gata4过表达在人类心脏成纤维细胞中同样抑制促纤维化信号。

核心结论

  • 在CFs中过表达Gata4可能通过抑制纤维化、改善舒张功能障碍成为HFpEF有前景的治疗策略。

研究设计与样本

  • 使用Tcf21iCre/Tomato/MGTH2A转基因小鼠,他莫昔芬诱导CFs表达MGTH并进行谱系追踪。
  • 采用高脂饮食联合一氧化氮合酶抑制建立HFpEF模型小鼠。
  • 开展bulk RNA测序、单细胞RNA测序和空间转录组学分析纤维化机制及重编程疗效。
  • 生成他莫昔芬诱导、在CFs中过表达各重编程因子的新转基因小鼠以研究单因子效应。
  • 分析重编程因子在人类CFs中的作用。

主要发现

  • MGTH过表达的心脏重编程改善了HFpEF的舒张功能障碍、心肌肥厚、纤维化、炎症和毛细血管丢失。
  • 心脏重编程将约1%的驻留CFs转化为诱导心肌细胞。
  • Bulk RNA-seq显示MGTH过表达上调与心脏收缩相关的基因,抑制胎儿基因程序(Nppa和Nppb)及促炎和纤维化特征。
  • 单细胞RNA测序和空间转录组学显示多个CF簇上调纤维化基因诱导弥漫性间质纤维化,而不同CF簇在HFpEF中产生局灶性血管周围纤维化,MGTH过表达逆转这些促纤维化改变。
  • 4个重编程因子中仅Gata4过表达通过抑制CF活化减少纤维化并改善HFpEF舒张功能障碍,且不产生新的诱导心肌细胞;Gata4过表达也抑制人类CFs的促纤维化特征。

临床怎么用

  • 对HFpEF患者,CFs中Gata4过表达可能作为抑制纤维化、改善舒张功能的候选治疗方向。

局限性

  • 研究主要基于小鼠HFpEF模型与体外人类CFs分析,尚未提供临床人体试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major health concern. Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to cardiac fibrosis and diastolic dysfunction, which are hallmarks of HFpEF. Interstitial and perivascular cardiac fibrosis correlates with poor prognosis in HFpEF; however, mechanisms of fibrosis remain poorly elucidated, and targeted therapies are lacking. Cardiac reprogramming is a promising therapeutic approach for myocardial infarction that facilitates cardiac regeneration and antifibrosis action through Mef2c/Gata4/Tbx5/Hand2 (MGTH) overexpression in resident CFs. However, the efficacy of this approach on HFpEF is yet to be established. METHODS: Herein, we examined the effects of cardiac reprogramming in HFpEF using Tcf21iCre/Tomato/MGTH2A transgenic mice, which expressed both MGTH and reporter expression in CFs for cardiac reprogramming and lineage tracing upon tamoxifen administration. To establish HFpEF model mice, we used a combination of a high-fat diet and nitric oxide synthase inhibition. Bulk RNA-sequencing, single-cell RNA-sequencing, and spatial transcriptomics were conducted to determine fibrotic mechanisms and the efficacy of cardiac reprogramming in HFpEF. We generated new tamoxifen-inducible transgenic mice overexpressing each reprogramming factor in CFs to investigate the effect of single factors. Last, we analyzed the effect of reprogramming factors in human CFs. RESULTS: Cardiac reprogramming with MGTH overexpression improved diastolic dysfunction, cardiac hypertrophy, fibrosis, inflammation, and capillary loss in HFpEF. Cardiac reprogramming converted approximately 1% of resident CFs into induced cardiomyocytes. Bulk RNA-seq indicated that MGTH overexpression upregulated genes related to heart contraction and suppressed the fetal gene program (Nppa and Nppb) and proinflammatory and fibrotic signatures. Single-cell RNA-sequencing and spatial transcriptomics revealed that multiple CF clusters upregulated fibrotic genes to induce diffuse interstitial fibrosis, whereas distinct CF clusters generated focal perivascular fibrosis in HFpEF. MGTH overexpression reversed these profibrotic changes. Among 4 reprogramming factors, only Gata4 overexpression in CFs reduced fibrosis and improved diastolic dysfunction in HFpEF by suppressing CF activation without generating new induced cardiomyocytes. Gata4 overexpression also suppressed profibrotic signatures in human CFs. CONCLUSIONS: Overexpressing Gata4 in CFs may be a promising therapeutic approach for HFpEF by suppressing fibrosis and improving diastolic dysfunction.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yamada, Sadahiro, Nakano, et al. Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation. 2024. PMID: 39673349. doi:10.1161/CIRCULATIONAHA.123.067504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。